-+ 0.00%
-+ 0.00%
-+ 0.00%

Silexion Therapeutics Corp. Announces Positive Preclinical Results for SIL204 in Lung Cancer, Preparing for Phase 2/3 Clinical Trial in 2026

Reuters·07/09/2025 13:16:24

Please log in to view news